HONG KONG – Clinical-stage biopharma Taiwanj Pharmaceuticals Co. Ltd. said its drug candidate, JKB-122, for treating nonalcoholic fatty liver disease (NAFLD) showed positive results in a 12-week phase II study in Taiwan. Encouraged by those positive results, the company already has plans to push the compound to the next clinical stage in its homeland, with an IND expected to be filed in the second quarter of next year.